Itamar Shalit

Dept of Cellular Biology & Histology, Schneider Children's Medical Center of Israel, Tel-Aviv University, Israel

Itamar Shalit

Academic positions:
- Director of the Pediatric Infectious Disease Unit, Schneider Children's Hospital, Israel
- Former Director General of Schneider Children's Hospital and Carmel Hospital in Israel

Any industry positions (last five years):
Dr. Shalit's experience in research and clinical trials includes collaborations and consultancy for international pharmaceutical companies such as Bayer AG, Smith-Klein-Beecham, Eli Lilly, Glaxo Group Research and Miles Pharmaceuticals. He is also a scientific advisory board member for Bioline RX.

Research interests:
Dr Shalit's main areas of research include the study of immunomodulatory effects of quinolones, the study of anti-inflammatory and signal transduction mechanisms and study of novel anti-fungal agents and their combinations.

Any other information:
Dr. Shalit is a long-standing member of several Israel Ministry of Health committees focused on designing the national vaccination program, preparedness against bio-terrorism and eradication of poliomyelitis.

He received a Certificate of Appreciation from the World Health Organization (WHO) for his contribution and outstanding efforts and success in poliomyelitis eradication in Israel. Dr Shalit is the author of over 70 publications in leading scientific journals and chapters in textbooks and is currently Chairman of the Israeli Society for Infectious Diseases.

Any competing interests declared are displayed with individual evaluations.

Section Head: Infectious Diseases > Bioterrorism (since 16 November 2005)

Itamar Shalit is a Section Head for Bioterrorism, part of the INFECTIOUS DISEASES Faculty. The role of a Section Head is to work with their Co-Section Head(s) to divide the Section (sub-specialty area) into its component areas of research, nominate leaders in those areas as Faculty Members, and offer ongoing oversight of the content within their Section. They are not asked to evaluate articles, although we do, of course, welcome them.